Education
About Us
Working with TipRanks
Follow Us
Tianda Pharmaceuticals Ltd. (HK:0455)
:0455
Top Page
Tianda Pharmaceuticals Ltd.
(0455)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.10
▲(4.00% Upside)
Tianda Pharmaceuticals Ltd. is currently facing significant financial and operational challenges. The most impactful factor is the company's weak financial performance, characterized by declining revenues and persistent losses. Technical indicators also suggest bearish momentum, while the valuation is hampered by a negative P/E ratio, though the high dividend yield offers some appeal.
Positive Factors
Diversified Product Portfolio
Tianda's diversified product portfolio across traditional Chinese medicine, prescription, and OTC products helps mitigate risks and tap into various market segments, providing resilience against sector-specific downturns.
Moderate Debt Levels
A moderate debt-to-equity ratio suggests manageable leverage, allowing Tianda Pharmaceuticals to maintain financial flexibility and invest in growth opportunities without excessive financial strain.
Stable Gross Profit Margin
A stable gross profit margin indicates that Tianda Pharmaceuticals can maintain cost efficiency in production, which is crucial for long-term profitability as the company works to improve its overall financial performance.
Negative Factors
Declining Revenue
The significant decline in revenue growth reflects challenges in market demand or competitive pressures, which could hinder the company's ability to sustain operations and invest in future growth.
Negative Cash Flow
Negative operating cash flow indicates inefficiencies in converting revenue into cash, which can limit Tianda's ability to fund operations, pay down debt, or invest in new projects, impacting long-term viability.
Persistent Losses
Persistent losses and negative profit margins highlight ongoing operational challenges, which could erode shareholder value and limit the company's capacity to reinvest in business development and innovation.
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$225.75M
Dividend YieldN/A
Average Volume (3M)84.94K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth-19.28%
EPS Growth-42.27%
CountryHK
Employees701
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.72
Price to Sales (P/S)1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company DescriptionTianda Pharmaceuticals Ltd. (0455) is a biotechnology and pharmaceutical company based in Hong Kong that focuses on the research, development, manufacturing, and marketing of a range of pharmaceutical products. The company primarily operates in the sectors of traditional Chinese medicine, prescription pharmaceuticals, and over-the-counter (OTC) products. Tianda is committed to advancing healthcare through innovative therapies, and its core product offerings include a variety of medications aimed at addressing chronic and acute health conditions.
How the Company Makes MoneyTianda Pharmaceuticals generates revenue through multiple streams, including the sale of prescription medications, OTC products, and traditional Chinese medicine. The company's revenue model is based on direct sales to healthcare providers, pharmacies, and hospitals, as well as distribution agreements with third-party partners. Key revenue streams include the licensing of its proprietary products and formulations, which allows the company to expand its market reach. Additionally, Tianda may benefit from collaborations with research institutions or other pharmaceutical companies that enhance its product development capabilities and market presence. Factors contributing to its earnings also include market demand for its diversified product portfolio and strategic marketing initiatives aimed at increasing brand awareness.
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 384.68M | 329.94M | 532.09M | 546.69M | 509.96M | 474.33M |
| Gross Profit | 176.28M | 152.02M | 255.53M | 251.52M | 241.22M | 258.99M |
| EBITDA | -9.97M | -49.49M | 15.66M | -19.89M | -5.14M | -6.25M |
| Net Income | -47.26M | -61.37M | -24.16M | -54.64M | -21.67M | -25.92M |
Balance Sheet | ||||||
| Total Assets | 804.77M | 765.02M | 917.29M | 1.09B | 1.16B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 103.77M | 85.69M | 162.44M | 343.44M | 334.00M | 234.98M |
| Total Debt | 98.81M | 127.44M | 113.60M | 141.05M | 160.43M | 145.53M |
| Total Liabilities | 260.34M | 259.36M | 325.35M | 434.23M | 375.08M | 342.97M |
| Stockholders Equity | 544.55M | 505.84M | 592.07M | 627.83M | 756.75M | 756.71M |
Cash Flow | ||||||
| Free Cash Flow | -43.08M | -52.30M | -116.04M | 54.73M | -61.98M | -184.08M |
| Operating Cash Flow | -26.10M | -9.70M | -49.76M | 79.11M | -8.23M | -37.63M |
| Investing Cash Flow | -42.53M | -31.77M | -69.10M | -12.20M | 86.35M | -137.73M |
| Financing Cash Flow | -59.61M | -30.65M | -57.39M | -28.98M | -1.29M | 90.75M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Negative
0.10
Price Trends
0.13
Negative
0.15
Negative
0.15
Negative
Market Momentum
>-0.01
Positive
24.16
Positive
11.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.13, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 24.16 is Positive, neither overbought nor oversold. The STOCH value of 11.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$250.02M | 38.21 | 0.72% | 3.60% | -5.98% | -81.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$573.47M | -3.12 | -40.38% | ― | -43.46% | -96.48% | |
48 Neutral | HK$195.88M | -38.73 | -8.71% | ― | 2.54% | 33.33% | |
46 Neutral | HK$444.42M | -32.11 | -1.16% | 7.59% | 59.60% | -351.02% | |
41 Neutral | HK$225.75M | -3.29 | -13.08% | ― | -19.28% | -42.27% | |
41 Neutral | HK$539.40M | -3.17 | ― | ― | ― | ― |
* Healthcare Sector Average
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.09
-47.37%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.40
0.19
95.54%
HK:1011
China NT Pharma Group Co., Ltd.
0.83
0.57
219.23%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.80
-0.01
-1.23%
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.15
0.07
87.50%
HK:8622
Huakang Biomedical Holdings Company Limited
0.40
0.22
119.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.